Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest HER2/neu Stories

2013-07-26 16:20:02

Singapore, July 27, 2013 - (ACN Newswire) - Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported in the July 2013 issue of PNAS. Out of the 1.5 million women diagnosed with breast cancer in the world annually, nearly one in seven of these is classified as triple negative. Patients with triple- negative breast cancer (TNBC) have tumours...

2013-07-23 08:31:59

Conference called scheduled for Wednesday, August 14, 2013 at 10 a.m. EST WORCESTER, Mass. and TORONTO, July 23, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today confirmed that it will be hosting a conference call with members of the Antigen Express, Inc. (www.antigenexpress.com) Scientific Advisory Board on Wednesday, August 14, 2013 at 10 a.m. EDT. Call-in particulars will be announced prior to the call. The call will include a...

2013-06-28 12:24:26

SAN DIEGO, June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin(®) (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with HER2-positive breast cancer in Europe. (Logo;...

2013-06-17 00:21:03

SAN DIEGO and SHANGHAI, June 16, 2013 /PRNewswire/ -- Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer. Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx...

2013-06-12 08:29:54

Unique abilities of AE37 to activate immune system highlighted WORCESTER, Mass. and TORONTO, June 12, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced an interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. Dr. Mittendorf is the Principal Investigator of the Company's AE37 clinical trial to test the ability of the novel immunotherapeutic agent to prevent relapse in patients who have had HER2-expressing breast cancer, the...

2013-06-05 12:30:44

Treatment Regimen Targets All HER2 Expressing Patients, including those 50% of patients for whom no therapies are available WORCESTER, Mass. and TORONTO, June 5, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced two presentations showing the strengths of AE37 as a viable and promising treatment option for patients who have had breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc....

2013-06-03 23:14:07

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. Chicago, Illinois (PRWEB) June 03, 2013 The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression...

2013-06-03 20:21:14

Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013 /PRNewswire/ -- MacroGenics, Inc. announced that results of the first-in-human study of margetuximab were reported during an oral abstract session today at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Howard A. Burris, M.D., FACP, first author and Chief Medical Officer of Sarah Cannon Research Institute, presented "Phase 1 study of...

2013-06-03 12:32:40

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of...

2013-06-01 08:21:28

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on final results from a cooperative group and NCI-sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer (mTNBC). Triple-negative breast cancer lacks progesterone and estrogen receptors and the HER2 biomarker that is present in most breast cancers, which makes standard therapy with...